TY - JOUR
T1 - Outcomes among high-risk and standard-risk multiple myeloma patients treated with high-dose chemotherapy and autologous hematopoietic stem-cell transplantation
AU - Kazmi, Syed M.
AU - Nusrat, Maliha
AU - Gunaydin, Hilal
AU - Cornelison, Amanda M.
AU - Shah, Nina
AU - Kebriaei, Partow
AU - Nieto, Yago
AU - Parmar, Simrit
AU - Popat, Uday R.
AU - Oran, Betul
AU - Shah, Jatin J.
AU - Orlowski, Robert Z.
AU - Champlin, Richard E.
AU - Qazilbash, Muzaffar H.
AU - Bashir, Qaiser
N1 - Funding Information:
The University of Texas MD Anderson Cancer Center is supported in part by the National Institutes of Health through Cancer Center Support Grant P30CA016672 .
Publisher Copyright:
© 2015 Elsevier Inc.
PY - 2015/11
Y1 - 2015/11
N2 - Background Conventional cytogenetics and interphase fluorescence in-situ hybridization (FISH) identify a high-risk multiple myeloma population characterized by poor response and short survival. Patients and Methods We compared outcomes between high-risk and standard-risk myeloma patients who underwent autologous hematopoietic stem-cell transplantation (auto-HCT) at our institution between January 2005 and December 2009. High-risk myeloma was defined as -13/del(13q) or hypodiploidy in at least 2 metaphases of conventional cytogenetics, or -17/del(17p), t(4;14), t(14;16), t(14;20), hypodiploidy (< 45 chromosomes excluding -Y), or chromosome 1 abnormalities (+1q, -1p, t(1;x)) on FISH or conventional cytogenetics. Results Of 670 myeloma patients, 74 (11%) had high-risk myeloma. These high-risk patients had significantly lower overall response rates (74% vs. 85%; P <.01), shorter median progression-free survival (10.3 vs. 32.4 months; P <.001), and shorter overall survival (28 months vs. not reached; P <.001) than the standard-risk patients. Having only 1 high-risk cytogenetic abnormality or experiencing at least very good partial remission after auto-HCT independently predicted improved progression-free survival and overall survival (P <.05) in high-risk patients. Conclusion Even in an era of novel therapies, cytogenetically identified high-risk myeloma patients have worse prognoses than standard-risk myeloma patients after auto-HCT, and having more than 1 high-risk cytogenetic abnormality further reduces survival.
AB - Background Conventional cytogenetics and interphase fluorescence in-situ hybridization (FISH) identify a high-risk multiple myeloma population characterized by poor response and short survival. Patients and Methods We compared outcomes between high-risk and standard-risk myeloma patients who underwent autologous hematopoietic stem-cell transplantation (auto-HCT) at our institution between January 2005 and December 2009. High-risk myeloma was defined as -13/del(13q) or hypodiploidy in at least 2 metaphases of conventional cytogenetics, or -17/del(17p), t(4;14), t(14;16), t(14;20), hypodiploidy (< 45 chromosomes excluding -Y), or chromosome 1 abnormalities (+1q, -1p, t(1;x)) on FISH or conventional cytogenetics. Results Of 670 myeloma patients, 74 (11%) had high-risk myeloma. These high-risk patients had significantly lower overall response rates (74% vs. 85%; P <.01), shorter median progression-free survival (10.3 vs. 32.4 months; P <.001), and shorter overall survival (28 months vs. not reached; P <.001) than the standard-risk patients. Having only 1 high-risk cytogenetic abnormality or experiencing at least very good partial remission after auto-HCT independently predicted improved progression-free survival and overall survival (P <.05) in high-risk patients. Conclusion Even in an era of novel therapies, cytogenetically identified high-risk myeloma patients have worse prognoses than standard-risk myeloma patients after auto-HCT, and having more than 1 high-risk cytogenetic abnormality further reduces survival.
KW - Cytogenetics
KW - Multiple myeloma
KW - Prognosis
KW - Risk stratification
KW - Stem-cell transplantation
UR - http://www.scopus.com/inward/record.url?scp=84947043709&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84947043709&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2015.07.641
DO - 10.1016/j.clml.2015.07.641
M3 - Article
C2 - 26361647
AN - SCOPUS:84947043709
SN - 2152-2650
VL - 15
SP - 687
EP - 693
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
IS - 11
ER -